Sundeep Viswanathan, MD
Cardiovascular Disease · Aurora, CONPI 1790947166
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 61.4% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2019 at $13,906 and has fallen 87.9% since, to $1,679 in 2025. Among cardiovascular disease clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $114.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$13K
- Heartflow, Inc.$2K
- Boston Scientific$2K
- Abbott$867
- Medtronic$556
- Novartis$473
- plus $3K from 28 others
What the payments were for
- Speaking & faculty fees$12,30058%
- Travel & lodging$1,3806%
- Food & beverage$7,56036%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 26 | $13,032 |
| Heartflow, Inc. | 19 | $2,101 |
| Boston Scientific | 13 | $1,516 |
| Abbott | 10 | $867 |
| Medtronic(2 entities) | 4 | $556 |
| Novartis | 21 | $473 |
| Impulse Dynamics (USA) Inc. | 5 | $370 |
| Pfizer | 15 | $234 |
| Inari Medical, Inc. | 1 | $215 |
| Cvrx, Inc. | 4 | $209 |
| Amgen | 14 | $206 |
| E.r. Squibb & Sons, L.L.C. | 10 | $194 |
| Novo Nordisk | 3 | $185 |
| Penumbra, Inc. | 1 | $173 |
| Cleerly, Inc. | 2 | $161 |
| Astellas Pharma US Inc | 7 | $119 |
| Sanofi-aventis U.S. LLC | 6 | $104 |
| Boehringer Ingelheim | 4 | $68 |
| Edwards Lifesciences | 2 | $58 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $58 |
| Abiomed | 2 | $53 |
| Bayer | 2 | $48 |
| Merck | 2 | $38 |
| Baxter Healthcare | 1 | $30 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $28 |
| Sanofi | 1 | $25 |
| Bridgebio Pharma, Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Philips North America LLC | 1 | $16 |
| Lundbeck LLC | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Akcea Therapeutics, Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$12,664
- FFRct$1,446
- WATCHMAN Access System$1,166
- OPTIMIZER$627
- MitraClip$420
- TRICLIP$295
- FLOWTRIEVER CATHETER, S$215
- CT THROMBECTOMY SYSTEM KIT$215
- Indigo System$173
- SYMPLICITY G3$173
- Resolute$165
- Barostim Neo System$146
- Cleerly Ischemia$140
- Cleerly Labs$140
- RESONATE$123
- CoreValve Evolut$120
- Watchman$114
- Mitra Clip system$105
How this compares
$21,240 in reported general payments places this provider in the 90th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 220 | $258,548 |
| XareltoRivaroxaban | 94 | $105,383 |
| EntrestoSacubitril/Valsartan | 43 | $66,273 |
| FarxigaDapagliflozin Propanediol | 34 | $40,252 |
| MultaqDronedarone Hcl | 20 | $35,420 |
| Repatha SyringeEvolocumab | 16 | $14,199 |
| Repatha SureclickEvolocumab | 11 | $7,419 |
| Metoprolol Succinate | 315 | $3,487 |
| Flecainide Acetate | 40 | $2,343 |
| Rosuvastatin Calcium | 164 | $2,123 |
| Losartan Potassium | 221 | $1,923 |
| Midodrine Hcl | 13 | $1,799 |
| Dofetilide | 20 | $1,753 |
| Ezetimibe | 51 | $1,738 |
| Carvedilol | 218 | $1,735 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $234 | $258,548220 claims |
| Johnson & JohnsonXarelto | $13,032 | $105,38394 claims |
| NovartisEntresto | $473 | $66,27343 claims |
| AstraZenecaFarxiga | $12 | $40,25234 claims |
| Sanofi-aventis U.S. LLCMultaq | $104 | $35,42020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Aurora
- Payal KohliAurora$1.7M
- Marc BonacaAurora$703K
- William SauerAurora$365K
- Rhonda MiyasakaAurora$128K
- Gregory SchwartzAurora$122K
- Edward GillAurora$96K
- Joseph AdewumiAurora$61K
- Charles FuenzalidaAurora$30K
- Christina HealyAurora$25K
- Nelson PragerAurora$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.